Skip to main content

Oncology

FDA Approvals, Lung Cancer, Oncology

Opdivo plus Yervoy and Limited Chemotherapy Approved as First-Line Therapy for Metastatic NSCLC, Regardless of PD-L1 Expression

FDA Approvals, Lung Cancer, Oncology

Tecentriq plus Avastin First Immunotherapy Regimen Approved for Metastatic Hepatocellular Carcinoma

FDA Approvals, Lung Cancer, Oncology

Tecentriq Approved as First-Line Therapy for Metastatic NSCLC with High PD-L1 Expression

FDA Approvals, Lung Cancer, Oncology

Opdivo-Yervoy First Immunotherapy Combo Approved for First-Line Therapy of Patients with Metastatic NSCLC

FDA Approvals, Urothelial Cancer, Oncology

Jelmyto First FDA-Approved Therapy for Low-Grade Upper-Tract Urothelial Cancer

Multiple Myeloma, Oncology

Novel BCMA-Directed CAR T-Cell Therapy Had Excellent Responses in Heavily Pretreated Patients with Multiple Myeloma

Phoebe Starr

Leukemia, Oncology

Venetoclax plus Intensive Chemotherapy Shows Promising Results in All Patients with Acute Myeloid Leukemia

Chase Doyle

Leukemia, Oncology

All-Oral Time-Limited Combination Treatment for CLL or SLL Shows Early Impressive Efficacy

Wayne Kuznar

Leukemia, Oncology

Investigational Oral Form of Azacitidine Improves Survival Maintenance Therapy in Patients with Acute Myeloid Leukemia

Wayne Kuznar

Leukemia, Oncology

First-Line Acalabrutinib-Based Triplet Therapy Leads to Undetectable Minimal Residual Disease in CLL

Wayne Kuznar

Page 6 of 27
Results 51 - 60 of 262